Login to Your Account

Other News To Note

Monday, April 11, 2011
Polaris Group, of San Diego, said preclinical data for ADI-PEG-20, pegylated arginine deiminase, showed that it may effectively treat acute myeloid leukemia, glioblastoma multiforme and bladder cancer. In those cancers, hypermethylation of a promoter gene for arginosuccinate synthetase leads to a deficiency of the enzyme, which causes tumors to be reliant on externally supplied arginine. ADI-PEG-20 degrades arginine, depriving the tumor of that nutrient. Polaris is preparing to begin pivotal Phase III trials of the drug in hepatocellular carcinoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription